Top

Published in:

01-12-2020 | Obesity | Review

Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review

Authors: Giuseppe Lisco, Anna De Tullio, Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Vincenzo Triggiani

Published in: Endocrine | Issue 3/2020

Abstract

Purpose

Epidemiological data suggest that comorbid patients, mostly those with type 2 diabetes (T2D), are predisposed to poor prognosis in Coronavirus disease 2019 (COVID-19), leading to serious healthcare concerns. The aim of the present manuscript is to review the main relevant mechanisms possibly contributing to worsen the clinical course of COVID-19 in T2D.

Results

Poor glucose control, high glycaemic variability and diabetes-related comorbidities at baseline, particularly cardiovascular diseases and obesity, contribute in worsening the prognosis in the above-mentioned cluster of patients. Moreover, both a lower efficient innate immune system response and cytokine dysregulation predispose patients with T2D to impaired viral clearance and more serious pulmonary and systemic inflammation once the SARS-CoV-2 infection occurred. Inconclusive data are currently available for specifically indicate or contraindicate concurrent medications for managing T2D and its comorbidities in infected patients.

Conclusions

T2D individuals should be considered as more vulnerable to COVID-19 than general population, and thus require adequate advices about hygienic tips to protect themselves during the pandemic. A careful management of glucose levels and diabetes-related comorbidities remains essential for avoiding further complications, and patient monitoring during the pandemic should be performed also at distance by means of telemedicine. Further studies are needed to clarify whether medications normally used for managing T2D and its associated comorbidities could have a protective or detrimental effect on COVID-19 clinical course.

P. Zhou, X. Lou Yang, X.G. Wang et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798), 270–273 (2020). https://doi.org/10.1038/s41586-020-2012-7CrossRefPubMedPubMedCentral

A.E. Gorbalenya, S.C. Baker, R.S. Baric et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5(4), 536–544 (2020). https://doi.org/10.1038/s41564-020-0695-zCrossRef

P.G. Auwaerter, Coronavirus COVID-19 (SARS-CoV-2). Johns Hopkins ABX Guide (The Johns Hopkins University, 2020). https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540747/all/Coronavirus_COVID_19__SARS_CoV_2_. Accessed 16 Jul 2020

F. Wu, S. Zhao, B. Yu et al. A new coronavirus associated with human respiratory disease in China. Nature 579(7798), 265–269 (2020). https://doi.org/10.1038/s41586-020-2008-3CrossRefPubMedPubMedCentral

R. Lu, X. Zhao, J. Li et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224), 565–574 (2020). https://doi.org/10.1016/S0140-6736(20)30251-8CrossRefPubMedPubMedCentral

Y.R. Guo, Q.D. Cao, Z.S. Hong et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil. Med. Res. 7(1), 11 (2020). https://doi.org/10.1186/s40779-020-00240-0CrossRefPubMedPubMedCentral

W. Ji, W. Wang, X. Zhao, J. Zai, X. Li, Cross‐species transmission of the newly identified coronavirus 2019‐nCoV. J. Med. Virol. 92(4), 433–440 (2020). https://doi.org/10.1002/jmv.25682CrossRefPubMedPubMedCentral

Z. Liu, X. Xiao, X. Wei et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2. J. Med. Virol. 92, 595–601 (2020). https://doi.org/10.1002/jmv.25726CrossRefPubMed

K.G. Andersen, A. Rambaut, W.I. Lipkin et al. The proximal origin of SARS-CoV-2. Nat. Med. 26, 450–452 (2020). https://doi.org/10.1038/s41591-020-0820-9CrossRefPubMed

10.

Virus origin/Reducing animal-human transmission of emerging pathogens. https://www.who.int/health-topics/coronavirus/who-recommendations-to-reduce-risk-of-transmission-of-emerging-pathogens-from-animals-to-humans-in-live-animal-markets. Accessed 10 Apr 2020

11.

W.B. Yu, G.D. Tang, L. Zhang, R.T. Corlett, Decoding the evolution and transmissions of the novel pneumonia coronavirus (SARS-CoV-2 / HCoV-19) using whole genomic data. Zool. Res. 41(3), 247–257 (2020). https://doi.org/10.24272/j.issn.2095-8137.2020.022CrossRefPubMedPubMedCentral

12.

M. Lipsitch, D.L. Swerdlow, L. Finelli, Defining the epidemiology of Covid-19 - studies needed. N. Engl. J. Med. 382(13), 1194–1196 (2020). https://doi.org/10.1056/NEJMp2002125CrossRefPubMed

13.

J. Sun, W.T. He, L. Wang et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol. Med. 26(5), 483–495 (2020). https://doi.org/10.1016/j.molmed.2020.02.008CrossRefPubMedPubMedCentral

14.

X. Li, J. Zai, X. Wang, Y. Li, Potential of large “first generation” human-to-human transmission of 2019-nCoV. J. Med. Virol. 92(4), 448–454 (2020). https://doi.org/10.1002/jmv.25693CrossRefPubMedPubMedCentral

15.

WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed 10 Apr 2020

16.

Y. Cao, X. Liu, L. Xiong, K. Cai, Imaging and clinical features of patients with 2019 novel coronavirus SARS‐CoV‐2: a systematic review and meta‐analysis. J. Med. Virol. (2020). https://doi.org/10.1002/jmv.25822

17.

Z. Xu, L. Shi, Y. Wang et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020]. Lancet Respir. Med. 8(4), 420–422 (2020). https://doi.org/10.1016/S2213-2600(20)30076-XCrossRefPubMedPubMedCentral

18.

B. Hanley, S.B. Lucas, E. Youd et al. Autopsy in suspected COVID-19 cases. J. Clin. Pathol. 73(5), 239–242 (2020). https://doi.org/10.1136/jclinpath-2020-206522CrossRefPubMed

19.

S. Tian, W. Hu, L. Niu, H. Liu, H. Xu, S.Y. Xiao, Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J. Thorac. Oncol. 15(5), 700–704 (2020). https://doi.org/10.1016/j.jtho.2020.02.010CrossRefPubMedPubMedCentral

20.

L. Chen, M. Liu, Z. Zhang et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. Br. J. Ophthalmol. 104(6), 748–751 (2020). https://doi.org/10.1136/bjophthalmol-2020-316304CrossRefPubMed

21.

P. Wu, F. Duan, C. Luo et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 138(5), 575–578 (2020). https://doi.org/10.1001/jamaophthalmol.2020.1291CrossRefPubMedPubMedCentral

22.

K.S. Cheung, I.F.N. Hung, P.P.Y. Chan et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples From a Hong Kong Cohort: systematic review and meta-analysis. Gastroenterology S0016-5085(20), 30448–0 (2020). https://doi.org/10.1053/j.gastro.2020.03.065CrossRef

23.

Y. Tian, L. Rong, W. Nian, Y. He, Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol. Ther. 51(9), 843–851 (2020). https://doi.org/10.1111/apt.15731CrossRefPubMedPubMedCentral

24.

F. D’Amico, D.C. Baumgart, S. Danese, L. Peyrin-Biroulet, Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management. Clin. Gastroenterol. Hepatol. 18(8), 1663–1672 (2020). https://doi.org/10.1016/j.cgh.2020.04.001CrossRefPubMedPubMedCentral

25.

L. Mao, H. Jin, M. Wang et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 77(6), 1–9 (2020). https://doi.org/10.1001/jamaneurol.2020.1127CrossRefPubMedCentral

26.

S. Recalcati, Cutaneous manifestations in COVID-19: a first perspective. J. Eur. Acad. Dermatol. Venereol. 34(5), e212–e213 (2020). https://doi.org/10.1111/jdv.16387CrossRefPubMed

27.

C. Ronco, T. Reis, Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat. Rev. Nephrol. 16(6), 308–310 (2020). https://doi.org/10.1038/s41581-020-0284-7CrossRefPubMed

28.

V. Fanelli, M. Fiorentino, V. Cantaluppi et al., Acute kidney injury in SARS-CoV-2 infected patients. Crit. Care. 24(1), 155 2020). https://doi.org/10.1186/s13054-020-02872-zCrossRefPubMedPubMedCentral

29.

A. Lovato, C. de Filippis, Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. (2020). https://doi.org/10.1177/0145561320920762

30.

G. Tavazzi, C. Pellegrini, M. Maurelli et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur. J. Heart Fail. 22(5), 911–915 (2020). https://doi.org/10.1002/ejhf.1828CrossRefPubMed

31.

Y.Y. Zheng, Y.T. Ma, J.Y. Zhang, X. Xie, COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 17(5), 259–260 (2020). https://doi.org/10.1038/s41569-020-0360-5CrossRefPubMed

32.

Y. Hu, H. Deng, L. Huang et al. Analysis of characteristics in death patients with COVID-19 pneumonia without underlying diseases. Acad. Radiol. 27(5), 752 (2020). https://doi.org/10.1016/j.acra.2020.03.023CrossRefPubMedPubMedCentral

33.

G. Onder, G. Rezza, S. Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA (2020). https://doi.org/10.1001/jama.2020.4683

34.

J.L. Vincent, F.S. Taccone, Understanding pathways to death in patients with COVID-19. Lancet. Respir. Med. 8(5), 430–432 (2020). https://doi.org/10.1016/S2213-2600(20)30165-XCrossRef

35.

Q. Ye, B. Wang, J. Mao et al. Epidemiological analysis of COVID-19 and practical experience from China. J. Med Virol. 92(7), 755–769 (2020). https://doi.org/10.1002/jmv.25813CrossRefPubMed

36.

Kang Y.-J. Mortality rate of infection with COVID-19 in Korea from the perspective of underlying disease. Disaster Med Public Health Prep. 1–3 (2020). https://doi.org/10.1017/dmp.2020.60

37.

Z. Shahid, R. Kalayanamitra, B. McClafferty et al. COVID-19 and older adults: what we know. J. Am. Geriatr. Soc. 68(5), 926–929 (2020). https://doi.org/10.1111/jgs.16472CrossRefPubMedPubMedCentral

38.

G. Onder, G. Rezza, S. Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323(18), 1775–1776 (2020). https://doi.org/10.1001/jama.2020.4683CrossRefPubMed

39.

P. Saeedi, I. Petersohn, P. Salpea et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 157, 107843 (2019). https://doi.org/10.1016/j.diabres.2019.107843CrossRefPubMed

40.

G.P. Fadini, M.L. Morieri, E. Longato, A. Avogaro, Prevalence and impact of diabetes among people infected with SARS-CoV-2. J. Endocrinol. Investig. 43(6), 867–869 (2020). https://doi.org/10.1007/s40618-020-01236-2CrossRef

41.

J.J. Zhang, X. Dong, Y.Y. Cao et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75(7), 1730–1741 (2020). https://doi.org/10.1111/all.14238CrossRefPubMed

42.

S.A. Meo, T. Al-Khlaiwi, A.M. Usmani et al. Biological and epidemiological trends in the prevalence and mortality due to outbreaks of novel coronavirus COVID-19. J. King Saud. Univ. Sci. 32(4), 2495–2499 (2020). https://doi.org/10.1016/j.jksus.2020.04.004CrossRefPubMedPubMedCentral

43.

N. Chow, K. Fleming-Dutra, R. Gierke et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. Morb. Mortal. Wkly Rep. 69(13), 382–386 (2020). https://doi.org/10.15585/mmwr.mm6913e2CrossRef

44.

W.J. Guan, Z.Y. Ni, Y. Hu et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382(18), 1708–1720 (2020). https://doi.org/10.1056/NEJMoa2002032CrossRefPubMed

45.

F. Zhou, T. Yu, R. Du et al. Articles Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020). https://doi.org/10.1016/S0140-6736(20)30566-3CrossRefPubMedPubMedCentral

46.

P.K. Bhatraju, B.J. Ghassemieh, M. Nichols et al. Covid-19 in critically ill patients in the seattle region—case series. N. Engl. J. Med. 382(21), 2012–2022 (2020). https://doi.org/10.1056/NEJMoa2004500CrossRefPubMed

47.

R. Huang, L. Zhu, L. Xue et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study. PLoS Negl. Trop. Dis. 14(5), e0008280 (2020). https://doi.org/10.1371/journal.pntd.0008280CrossRefPubMedPubMedCentral

48.

X. Yang, Y. Yu, J. Xu et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [published correction appears in Lancet Respir Med. 2020 Apr;8(4):e26]. Lancet Respir. Med. 8(5), 475–481 (2020). https://doi.org/10.1016/S2213-2600(20)30079-5CrossRefPubMedPubMedCentral

49.

Y. Du, L. Tu, P. Zhu et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. a retrospective observational study. Am. J. Respir. Crit. Care Med. 201(11), 1372–1379 (2020). https://doi.org/10.1164/rccm.202003-0543OCCrossRefPubMedPubMedCentral

50.

W. Abu-Ashour, L.K. Twells, J.E. Valcour, J.M. Gamble, Diabetes and the occurrence of infection in primary care: a matched cohort study. BMC Infect. Dis. 18(1), 67 (2018). https://doi.org/10.1186/s12879-018-2975-2CrossRefPubMedPubMedCentral

51.

H. Wu, E.S.H. Lau, R.C.W. Ma et al. Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001–2016: a retrospective cohort study. Diabetologia 63(4), 757–766 (2020). https://doi.org/10.1007/s00125-019-05074-7CrossRefPubMed

52.

R. Allard, P. Leclerc, C. Tremblay, T.N. Tannenbaum, Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care. 33(7), 1491–1493 (2010). https://doi.org/10.2337/dc09-2215CrossRefPubMedPubMedCentral

53.

R.B. Klekotka, E. Mizgała, W. Król, The etiology of lower respiratory tract infections in people with diabetes. Pneumonol. Alergol. Pol. 83(5), 401–408 (2015). https://doi.org/10.5603/PiAP.2015.0065CrossRefPubMed

54.

A. Badawi, S.G. Ryoo, Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J. Infect. Dis. 49, 129–133 (2016). https://doi.org/10.1016/j.ijid.2016.06.015CrossRefPubMedPubMedCentral

55.

M. Goeijenbier, T.T. van Sloten, L. Slobbe et al. Benefits of flu vaccination for persons with diabetes mellitus: a review. Vaccine 35(38), 5095–5101 (2017). https://doi.org/10.1016/j.vaccine.2017.07.095CrossRefPubMed

56.

A. Hussain, B. Bhowmik, N.C. do Vale Moreira, COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin. Pract. 162, 108142 (2020). https://doi.org/10.1016/j.diabres.2020.108142CrossRefPubMedPubMedCentral

57.

J.A. Critchley, I.M. Carey, T. Harris et al. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 41(10), 2127–2135 (2018). https://doi.org/10.2337/dc18-0287CrossRefPubMed

58.

K.D. Hulme, L.A. Gallo, K.R. Short, Influenza virus and glycemic variability in diabetes: a killer combination? Front. Microbiol. 8, 861 (2017). https://doi.org/10.3389/fmicb.2017.00861CrossRefPubMedPubMedCentral

59.

L. Zhu, Z.G. She, X. Cheng et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 31(6), 1068–1077 (2020). https://doi.org/10.1016/j.cmet.2020.04.021CrossRefPubMedPubMedCentral

60.

J. Wu, J. Huang, G. Zhu et al. Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study. BMJ Open Diabetes Res Care 8(1), e001476 (2020). https://doi.org/10.1136/bmjdrc-2020-001476CrossRefPubMed

61.

Z.H. Wu, Y. Tang, Q. Cheng, Diabetes increases the mortality of patients with COVID-19: a meta-analysis. Acta Diabetol. 1–6 (2020). https://doi.org/10.1007/s00592-020-01546-0

62.

A.K. Singh, R. Gupta, A. Ghosh, A. Misra, Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab. Syndr. 14(4), 303–310 (2020). https://doi.org/10.1016/j.dsx.2020.04.004CrossRefPubMedPubMedCentral

63.

O. Takeuchi, S. Akira, Innate immunity to virus infection. Immunol. Rev. 227(1), 75–86 (2009). https://doi.org/10.1111/j.1600-065X.2008.00737.xCrossRefPubMedPubMedCentral

64.

G. Li, Y. Fan, Y. Lai et al. Coronavirus infections and immune responses. J. Med Virol. 92(4), 424–432 (2020). https://doi.org/10.1002/jmv.25685CrossRefPubMedPubMedCentral

65.

Y. Chen, L. Li, SARS-CoV-2: virus dynamics and host response. Lancet Infect. Dis. 20(5), 515–516 (2020). https://doi.org/10.1016/S1473-3099(20)30235-8CrossRefPubMedPubMedCentral

66.

H. Li, L. Liu, D. Zhang et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 395(10235), 1517–1520 (2020). https://doi.org/10.1016/S0140-6736(20)30920-XCrossRefPubMedPubMedCentral

67.

J.H. Kim, K. Park, S.B. Lee et al. Relationship between natural killer cell activity and glucose control in patients with type 2 diabetes and prediabetes. J. Diabetes Investig. 10(5), 1223–1228 (2019). https://doi.org/10.1111/jdi.13002CrossRefPubMedPubMedCentral

68.

A. Lecube, G. Pachón, J. Petriz et al. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. G. Sesti (ed.) PLoS ONE 6(8), e23366 (2011). https://doi.org/10.1371/journal.pone.0023366

69.

W.M.T. Kuwabara, C.N.F. Yokota, R. Curi, T.C. Alba-Loureiro, Obesity and type 2 diabetes mellitus induce lipopolysaccharide tolerance in rat neutrophils. Sci. Rep. 8(1), 17534 (2018). https://doi.org/10.1038/s41598-018-35809-2CrossRefPubMedPubMedCentral

70.

T. Zhou, Z. Hu, S. Yang et al. Role of adaptive and innate immunity in type 2 diabetes mellitus. J. Diabetes Res. 2018, 7457269 (2018). https://doi.org/10.1155/2018/7457269CrossRefPubMedPubMedCentral

71.

R. Kartika, D. Purnamasari, S. Pradipta et al. Impact of low interferon-γ and il-10 levels on tnf-α and il-6 production by pha-induced pbmcs in type 2 diabetes mellitus. J. Inflamm. Res. 13, 187–193 (2020). https://doi.org/10.2147/JIR.S245064CrossRefPubMedPubMedCentral

72.

W. Guo, M. Li, Y. Dong et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. (2020). https://doi.org/10.1002/dmrr.3319

73.

E. Maddaloni, R. Buzzetti, Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab. Res. Rev. e33213321 (2020). https://doi.org/10.1002/dmrr.3321

74.

P.R. Ling, R.J. Smith, B.R. Bistrian, Acute effects of hyperglycemia and hyperinsulinemia on hepatic oxidative stress and the systemic inflammatory response in rats. Crit. Care Med. 35(2), 555–560 (2007). https://doi.org/10.1097/01.CCM.0000253310.02180.C2CrossRefPubMed

75.

P.R. Ling, R.J. Smith, B.R. Bistrian, Hyperglycemia enhances the cytokine production and oxidative responses to a low but not high dose of endotoxin in rats. Crit. Care Med. 33(5), 1084–1089 (2005). https://doi.org/10.1097/01.CCM.0000163225.88827.63CrossRefPubMed

76.

P. Mehta, D.F. McAuley, M. Brown et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229), 1033–1034 (2020). https://doi.org/10.1016/S0140-6736(20)30628-0CrossRefPubMedPubMedCentral

77.

P. Sarzi-Puttini, V. Giorgi, S. Sirotti et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin. Exp. Rheumatol. 38(2), 337–342 (2020)PubMed

78.

C. Huang, Y. Wang, X. Li et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223), 497–506 (2020). https://doi.org/10.1016/S0140-6736(20)30183-5CrossRefPubMedPubMedCentral

79.

D. McGonagle, K. Sharif, A. O’Regan, C. Bridgewood, The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev. 19(6), 102537 (2020). https://doi.org/10.1016/j.autrev.2020.102537CrossRefPubMedPubMedCentral

80.

C. Wu, X. Chen, Y. Cai et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 180(7), 1–11 (2020). https://doi.org/10.1001/jamainternmed.2020.0994CrossRefPubMedCentral

81.

S. Wan, Q. Yi, S. Fan et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv (2020). https://doi.org/10.1101/2020.02.10.20021832

82.

B. Diao, C. Wang, Y. Tan et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 11, 827 (2020). https://doi.org/10.1101/2020.02.18.20024364CrossRefPubMedPubMedCentral

83.

C.W. Tan, J.G.H. Low, W.H. Wong et al. Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability. Am. J. Hematol. 95(7), E156–E158 (2020). https://doi.org/10.1002/ajh.25822CrossRefPubMedPubMedCentral

84.

E. Terpos, I. Ntanasis-Stathopoulos, I. Elalamy et al. Hematological findings and complications of COVID-19. Am. J. Hematol. 95(7), 834–847 (2020). https://doi.org/10.1002/ajh.25829CrossRefPubMed

85.

A.C. Walls, Y.-J. Park, M.A. Tortorici, A. Wall, A.T. Mcguire, D.V. Correspondence, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020). https://doi.org/10.1016/j.cell.2020.02.058CrossRefPubMedPubMedCentral

86.

I. Hamming, W. Timens, M. Bulthuis, A. Lely, G. Navis, H. van Goor, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203(2), 631–637 (2004). https://doi.org/10.1002/path.1570CrossRefPubMedPubMedCentral

87.

H. Xu, L. Zhong, J. Deng et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J. Oral. Sci. 12(1), 1–5 (2020). https://doi.org/10.1038/s41368-020-0074-xCrossRef

88.

J. Wang, S. Zhao, M. Liu et al. ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism. medRxiv (2020). https://doi.org/10.1101/2020.02.05.20020545

89.

N. Alenina, M. Bader, ACE2 in BRain physiology and pathophysiology: evidence from transgenic animal models. Neurochem. Res. 44(6), 1323–1329 (2019). https://doi.org/10.1007/s11064-018-2679-4CrossRefPubMed

90.

D. Batlle, M.J. Soler, M. Ye, ACE2 and diabetes: ACE of ACEs? Diabetes 59(12), 2994–2996 (2010). https://doi.org/10.2337/db10-1205CrossRefPubMedPubMedCentral

91.

G.C. Douglas, M.K. O’Bryan, M.P. Hedger et al. The novel Angiotensin-Converting Enzyme (ACE) homolog, ACE2, is selectively expressed by adult leydig cells of the testis. Endocrinology 145(10), 4703–4711 (2004). https://doi.org/10.1210/en.2004-0443CrossRefPubMed

92.

M.J. Soler, J. Wysocki, D. Batlle, Angiotensin-converting enzyme 2 and the kidney. Exp. Physiol. Artic. 93, 549–556 (2008). https://doi.org/10.1113/expphysiol.2007.041350CrossRef

93.

J. Nicholls, M. Peiris, A.C.E. Good, A.C.E. bad, do battle in lung injury, SARS. Nat. Med. 11(8), 821–822 (2005). https://doi.org/10.1038/nm0805-821CrossRefPubMedPubMedCentral

94.

R. Pal, A.C.O.V.I.D.-19 Bhansali, Diabetes Mellitus, and ACE2: the conundrum. Diabetes Res. Clin. Pract. 162, 108132 (2020). https://doi.org/10.1016/j.diabres.2020.108132CrossRefPubMedPubMedCentral

95.

L. Fang, G. Karakiulakis, M. Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 8(4), e21 (2020). https://doi.org/10.1016/s2213-2600(20)30116-8CrossRefPubMedPubMedCentral

96.

A.E. Gracia-Ramos, Is the ACE2 overexpression a risk factor for COVID-19 infection? Arch. Med. Res. 51(4), 345–346 (2020). https://doi.org/10.1016/j.arcmed.2020.03.011CrossRefPubMedPubMedCentral

97.

T.R. Einarson, A. Acs, C. Ludwig, U.H. Panton, Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc. Diabetol. 17(1), 83 (2018). https://doi.org/10.1186/s12933-018-0728-6CrossRefPubMedPubMedCentral

98.

M. Madjid, P. Safavi-Naeini, S.D. Solomon, O. Vardeny. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. (2020). https://doi.org/10.1001/jamacardio.2020.1286

99.

C. Sardu, J. Gambardella, M.B. Morelli, X. Wang, R. Marfella, G. Santulli, Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J. Clin. Med. 9(5), 1417 (2020). https://doi.org/10.3390/jcm9051417CrossRefPubMedCentral

100.

Z. Varga, A.J. Flammer, P. Steiger et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234), 1417–1418 (2020). https://doi.org/10.1016/S0140-6736(20)30937-5CrossRefPubMedPubMedCentral

101.

R.M. Inciardi, L. Lup, G. Zaccone et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. (2020). https://doi.org/10.1001/jamacardio.2020.1096

102.

R.O. Bonow, G.C. Fonarow, P.T. O’Gara, C.W. Yancy, Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. (2020). https://doi.org/10.1001/jamacardio.2020.1105

103.

S.E. Kahn, R.L. Hull, K.M. Utzschneider, Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444(7121), 840–846 (2006). https://doi.org/10.1038/nature05482CrossRefPubMed

104.

N. Napoli, P. Pozzilli, Obesity and glucose metabolism. Multidisciplinary Approach to Obesity: Assessment to Treatment. (Springer International Publishing, 2015), pp. 107–119. https://doi.org/10.1007/978-3-319-09045-0_11

105.

P. González-Muniesa, M.-A. Mártinez-González, F.B. Hu et al. Obesity. Nat. Rev. Dis Prim. 3(1), 17034 (2017). https://doi.org/10.1038/nrdp.2017.34

106.

J. Yang, J. Hu, C. Zhu, Obesity aggravates COVID-19: a systematic review and meta-analysis [published online ahead of print]. J. Med. Virol. (2020). https://doi.org/10.1002/jmv.26237.

107.

W. Dietz, C. Santos-Burgoa, Obesity and its implications for COVID-19 mortality. Obesity 28(6), 1005 (2020). https://doi.org/10.1002/oby.22818CrossRefPubMed

108.

D.H. Ryan, E. Ravussin, S. Heymsfield, COVID 19 and the patient with obesity—the editors speak out. Obesity 28(5), 847 (2020). https://doi.org/10.1002/oby.22808CrossRefPubMed

109.

R.J. Jose, A. Manuel, Does coronavirus disease 2019 disprove the obesity paradox in acute respiratory distress syndrome? Obesity 28(6), 1007 (2020). https://doi.org/10.1002/oby.22835CrossRefPubMed

110.

C.M. Petrilli, S.A. Jones, J. Yang et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. MedRxiv (2020). https://doi.org/10.1101/2020.04.08.20057794

111.

S. Richardson, J.S. Hirsch, M. Narasimhan et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323(20), 2052–2059 (2020). https://doi.org/10.1001/jama.2020.6775CrossRefPubMedPubMedCentral

112.

A. Simonnet, M. Chetboun, J. Poissy et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity 28(7), 1195–1199 (2020). https://doi.org/10.1002/oby.22831CrossRefPubMed

113.

J. Lighter, M. Phillips, S. Hochman et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin. Infect. Dis. (2020), https://doi.org/10.1093/cid/ciaa415

114.

G. De Pergola, A. Nardecchia, V.A. Giagulli et al. Obesity and heart failure. Endocr. Metab. Immune Disord. Drug Targets 13(1), 51–57 (2013). https://doi.org/10.2174/1871530311313010007CrossRefPubMed

115.

D. Petrakis, D. Margină, K. Tsarouhas et al. Obesity—a risk factor for increased COVID‑19 prevalence, severity and lethality (Review). Mol. Med. Rep. 22(1), 9–19 (2020). https://doi.org/10.3892/mmr.2020.11127CrossRefPubMedPubMedCentral

116.

N. Stefan, A.L. Birkenfeld, M.B. Schulze, D.S. Ludwig, Obesity and impaired metabolic health in patients with COVID-19. Nat. Rev. Endocrinol. 16(7), 341–342 (2020). https://doi.org/10.1038/s41574-020-0364-6CrossRefPubMedPubMedCentral

117.

A.E. Dixon, U. Peters, The effect of obesity on lung function. Expert Rev Respir. Med. 12(9), 755–767 (2018). https://doi.org/10.1080/17476348.2018.1506331CrossRefPubMedPubMedCentral

118.

M.J. Butler, R.M. Barrientos, The impact of nutrition on COVID-19 susceptibility and long-term consequences. Brain Behav. Immun. 87, 53–54 (2020). https://doi.org/10.1016/j.bbi.2020.04.040CrossRefPubMedPubMedCentral

119.

S.J. Carter, M.N. Baranauskas, A.D. Fly, Considerations for obesity, vitamin D, and physical activity amid the COVID-19 pandemic. Obesity 28(7), 1176–1177 (2020). https://doi.org/10.1002/oby.22838CrossRefPubMed

120.

N. Sattar, I.B. McInnes, J.J.V. McMurray, Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation 142(1), 4–6 (2020). https://doi.org/10.1161/CIRCULATIONAHA.120.047659

121.

H. Zbinden-Foncea, M. Francaux, L. Deldicque, J.A. Hawley, Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2? Obesity (2020). https://doi.org/10.1002/oby.22849

122.

G. De Pergola, N. Pannacciulli, Coagulation and fibrinolysis abnormalities in obesity. J. Endocrinol. Investig. 25(10), 899–904 (2002). https://doi.org/10.1007/BF03344054CrossRef

123.

O. Seyam, J. Gandhi, G. Joshi et al. Obesity’s role in secondary male hypogonadism: a review of pathophysiology and management issues. SN Compr. Clin. Med. 1(6), 408–418 (2019). https://doi.org/10.1007/s42399-019-00056-7CrossRef

124.

V.A. Giagulli, J.M. Kaufman, A. Vermeulen, Pathogenesis of the decreased androgen levels in obese men. J. Clin. Endocrinol. Metab. 79(4), 997–1000 (1994). https://doi.org/10.1210/jcem.79.4.7962311CrossRefPubMed

125.

G. Corona, S. Bianchini, A. Sforza et al. Hypogonadism as a possible link between metabolic diseases and erectile dysfunction in aging men. Hormones 14(4), 569–578 (2015). https://doi.org/10.14310/horm.2002.1635CrossRefPubMed

126.

E.R. Simpson, S.R. Davis, Minireview: aromatase and the regulation of estrogen biosynthesis—some new perspectives. Endocrinology 142(11), 4589–4594 (2001). https://doi.org/10.1210/endo.142.11.8547CrossRefPubMed

127.

C. Ohlsson, A. Hammarstedt, L. Vandenput et al. Increased adipose tissue aromatase activity improves insulin sensitivity and reduces adipose tissue inflammation in male mice. Am. J. Physiol. Metab. 313(4), E450–E462 (2017). https://doi.org/10.1152/ajpendo.00093.2017CrossRef

128.

H.K. Lee, J.K. Lee, B. Cho, The role of androgen in the adipose tissue of males. World J. Mens. Health 31(2), 136–140 (2013). https://doi.org/10.5534/wjmh.2013.31.2.136CrossRefPubMedPubMedCentral

129.

V.A. Giagulli, M. Castellana, G. Lisco, V. Triggiani, Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology (2020). https://doi.org/10.1111/andr.12850

130.

Y. Gong, H. Xiao, C. Li et al. Elevated T/E2 ratio is associated with an increased risk of cerebrovascular disease in elderly men. PLoS ONE 8(4), e61598 (2013). https://doi.org/10.1371/journal.pone.0061598CrossRefPubMedPubMedCentral

131.

I.D. van Koeverden, M. de Bakker, S. Haitjema et al. Testosterone to oestradiol ratio reflects systemic and plaque inflammation and predicts future cardiovascular events in men with severe atherosclerosis. 115(2), 453–462 (2019). https://doi.org/10.1093/cvr/cvy188

132.

V.A. Giagulli, E. Guastamacchia, G. De Pergola et al. Testosterone deficiency in male: a risk factor for heart failure. Endocr. Metab. Immune Disord. Targets 13(1), 92–99 (2013). https://doi.org/10.2174/1871530311313010011CrossRef

133.

V.A. Giagulli, E. Guastamacchia, T. Magrone et al. Worse progression of COVID-19 in men: is testosterone a key factor? Andrology (2020). https://doi.org/10.1111/andr.12836

134.

R. Kassir, Risk of COVID-19 for patients with obesity. Obes. Rev. 21(6), e13034 (2020). https://doi.org/10.1111/obr.13034CrossRefPubMedPubMedCentral

135.

P.M. Ryan, N.M. Caplice, Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity 28(7), 1191–1194 (2020). https://doi.org/10.1002/oby.22843CrossRefPubMed

136.

W. Zhang, C. Li, B. Liu et al. Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis. Ann. Hepatol. 12(6), 892–900 (2013)CrossRefPubMed

137.

W. Zhang, Y.Z. Xu, B. Liu et al. Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. ScientificWorldJournal 2014, 603409 (2014). https://doi.org/10.1155/2014/603409CrossRefPubMedPubMedCentral

138.

C. Wu, Y. Liu, Y. Yang et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods [published online ahead of print]. Acta Pharm. Sin. B. 10(5), 766–788 (2020). https://doi.org/10.1016/j.apsb.2020.02.008CrossRefPubMedPubMedCentral

139.

R.W. Nesto, D. Bell, R.O. Bonow et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27(1), 256–263 (2004). https://doi.org/10.2337/diacare.27.1.256CrossRefPubMed

140.

A.D. Association, 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care 43, S98–S110 (2020). https://doi.org/10.2337/dc20-S009CrossRef

141.

A.J. Garber, Y. Handelsman, G. Grunberger et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary. Endocr. Pract. 26(1), 107 (2020). https://doi.org/10.4158/CS-2019-0472CrossRefPubMed

142.

R. Pal, S.K. Bhadada, Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res. Clin. Pract. 163, 108146 (2020). https://doi.org/10.1016/j.diabres.2020.108146CrossRefPubMedPubMedCentral

143.

A. Ceriello, A.P. Stoian, M. Rizzo, COVID-19 and diabetes management: What should be considered? Diabetes Res. Clin. Pract. 163, 108151 (2020). https://doi.org/10.1016/j.diabres.2020.108151CrossRefPubMedPubMedCentral

144.

D.K. Meyerholz, A.M. Lambertz, P.B. McCray, Dipeptidyl peptidase 4 distribution in the human respiratory tract implications for the middle east respiratory syndrome. Am. J. Pathol. 186(1), 78–86 (2016). https://doi.org/10.1016/j.ajpath.2015.09.014CrossRefPubMedPubMedCentral

145.

G. Iacobellis. COVID-19 and diabetes: can DPP4 inhibition play a role? Diabetes Res. Clin. Pract. 162(2020). https://doi.org/10.1016/j.diabres.2020.108125

146.

M. Letko, A. Marzi, V. Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5(4), 562–569 (2020). https://doi.org/10.1038/s41564-020-0688-yCrossRefPubMed

147.

M.F. Bassendine, S.H. Bridge, G.W. McCaughan, M.D. Gorrell. COVID-19 and comorbidities: a role for dipeptidyl peptidase 4 (DPP4) in disease severity? J. Diabetes (2020). https://doi.org/10.1111/1753-0407.13052

148.

E. Standl, O. Schnell, Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. Diabetes Res. Clin. Pract. 161(2020). https://doi.org/10.1016/j.diabres.2020.108054

149.

K.H. Sheahan, E.A. Wahlberg, M.P. Gilbert, An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad. Med J. 96(1133), 156–161 (2020). https://doi.org/10.1136/postgradmedj-2019-137186CrossRefPubMed

150.

S. Lim, T.J. Oh, J. Dawson, N. Sattar, Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. Diabetes Obes. Metab. 22(1), 6–15 (2020). https://doi.org/10.1111/dom.13850CrossRefPubMed

151.

E.M. Varin, B.A. McLean, J.A. Lovshin, Glucagon-like peptide-1 receptor agonists in adult patients with type 2 diabetes: review of cardiovascular outcome trials. Can. J. Diabetes 44(1), 68–77 (2020). https://doi.org/10.1016/j.jcjd.2019.08.011CrossRefPubMed

152.

J. Huang, H. Yi, C. Zhao et al. Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients. Int. J. Copd. 13, 3191–3202 (2018). https://doi.org/10.2147/COPD.S175145CrossRef

153.

S. Steven, K. Jurk, M. Kopp et al. Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice. Br. J. Pharmacol. 174(12), 1620–1632 (2017). https://doi.org/10.1111/bph.13549CrossRefPubMed

154.

M.H. Bloodworth, M. Rusznak, C.C. Pfister et al. Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus–induced type 2 responses and immunopathology. J. Allergy Clin. Immunol. 142(2), 683–687 (2018). https://doi.org/10.1016/j.jaci.2018.01.053CrossRefPubMedPubMedCentral

155.

S. Gentile, F. Strollo, A. Ceriello, COVID-19 infection in Italian people with diabetes: lessons learned for our future (an experience to be used). Diabetes Res Clin. Pract. 162, 108137 (2020). https://doi.org/10.1016/j.diabres.2020.108137CrossRefPubMedPubMedCentral

156.

S.O. Butler, I.F. Btaiche, C. Alaniz, Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy 25(7), 963–976 (2005). https://doi.org/10.1592/phco.2005.25.7.963CrossRefPubMed

157.

G.E. Umpierrez, A. Palacio, D. Smiley, Sliding Scale Insulin Use: Myth or Insanity? Am. J. Med. 120(7), 563–567 (2007). https://doi.org/10.1016/j.amjmed.2006.05.070CrossRefPubMed

158.

G.E. Umpierrez, D. Smiley, A. Zisman et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 Trial). Diabetes Care 30(9), 2181–2186 (2007). https://doi.org/10.2337/dc07-0295CrossRefPubMed

159.

J.R. Petrie, T.J. Guzik, R.M. Touyz, Diabetes, Hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can. J. Cardiol. 34(5), 575–584 (2018). https://doi.org/10.1016/j.cjca.2017.12.005CrossRefPubMed

160.

I.H. De Boer, S. Bangalore, A. Benetos et al. Diabetes and hypertension: a position statement by the American diabetes association. Diabetes Care 40(9), 1273–1284 (2017). https://doi.org/10.2337/dci17-0026CrossRefPubMed

161.

G. Wang, Y. Chen, L. Li et al. First-line renin–angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus. J. Hum. Hypertens. 32(7), 494–506 (2018). https://doi.org/10.1038/s41371-018-0066-xCrossRefPubMed

162.

R. Sommerstein, M.M. Kochen, F.H. Messerli, C. Gräni, Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J. Am. Heart Assoc. 9(7), e016509 (2020). https://doi.org/10.1161/JAHA.120.016509CrossRefPubMedPubMedCentral

163.

A.H.J. Danser, M. Epstein, D. Batlle, Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 75(6), 1382–1385 (2020). https://doi.org/10.1161/HYPERTENSIONAHA.120.15082CrossRefPubMed

164.

E.L. Schiffrin, J.M. Flack, S. Ito, P. Muntner, R.C. Webb, Hypertension and COVID-19. Am. J. Hypertens. 33(5), 373–374 (2020). https://doi.org/10.1093/ajh/hpaa057CrossRefPubMed

165.

M. Bengaluru Jayanna, J.G. Robinson, The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of “real world” practice in people with diabetes. Diabetes Obes. Metab. 21(S1), 17–27 (2019). https://doi.org/10.1111/dom.13701CrossRefPubMed

166.

I. Altun, F. Oz, S.C. Arkaya et al. Effect of statins on endothelial function in patients with acute coronary syndrome: a prospective study using adhesion molecules and flow-mediated dilatation. J. Clin. Med. Res. 6(5), 354–361 (2014). https://doi.org/10.14740/jocmr1863wCrossRefPubMedPubMedCentral

167.

S. Yuan, Statins may decrease the fatality rate of middle east respiratory syndrome infection. mBio 6(4), e01120 (2015). https://doi.org/10.1128/mBio.01120-15CrossRefPubMedPubMedCentral

168.

J. Deguine, G.M. Barton, MyD88: A central player in innate immune signaling. F1000Prime Rep. 6, 97 (2014). https://doi.org/10.12703/P6-97CrossRefPubMedPubMedCentral

169.

Is there a role for statin therapy in acute viral infections? American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/09/is-there-a-role-for-statin-therapy-in-acute-viral-infections-covid-19. Accessed 22 Apr 2020.

170.

A. Wang, W. Zhao, Z. Xu, J. Gu, Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res. Clin. Pract. 162, 108118 (2020). https://doi.org/10.1016/j.diabres.2020.108118CrossRefPubMedPubMedCentral

171.

S.R. Bornstein, F. Rubino, K. Khunti et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 8(6), 546–550 (2020). https://doi.org/10.1016/S2213-8587(20)30152-2CrossRefPubMedPubMedCentral

172.

B.M. Henry, M.H.S. de Oliveira, S. Benoit et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab Med. 58(7), 1021–1028 (2020). https://doi.org/10.1515/cclm-2020-0369CrossRefPubMed

173.

B. Russell, C. Moss, G. George et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience 14, 1022 (2020). https://doi.org/10.3332/ecancer.2020.1022CrossRefPubMedPubMedCentral

174.

L. Lin, L. Lu, W. Cao, T. Li, Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg. Microbes Infect. 9(1), 727–732 (2020). https://doi.org/10.1080/22221751.2020.1746199CrossRefPubMedPubMedCentral

175.

B. Liu, M. Li, Z. Zhou et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J. Autoimmun. 111, 102452 (2020). https://doi.org/10.1016/j.jaut.2020.102452CrossRefPubMedPubMedCentral

176.

R.M. Anderson, H. Heesterbeek, D. Klinkenberg, T.D. Hollingsworth, How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet 395(10228), 931–934 (2020). https://doi.org/10.1016/S0140-6736(20)30567-5CrossRefPubMedPubMedCentral

177.

D.C. Klonoff, G.E. Umpierrez, Letter to the Editor: COVID-19 in patients with diabetes: risk factors that increase morbidity. Metabolism 108, 154224 (2020). https://doi.org/10.1016/j.metabol.2020.154224CrossRefPubMedPubMedCentral

178.

Exercise, immunity and the COVID-19 pandemic. https://www.acsm.org/blog-detail/acsm-blog/2020/03/30/exercise-immunity-covid-19-pandemic. Accessed 21 Apr 2020.

179.

M. Puig-Domingo, M. Marazuela, A. Giustina, COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine 68(1), 2–5 (2020). https://doi.org/10.1007/s12020-020-02294-5CrossRefPubMedPubMedCentral

180.

AACE Position Statement: Coronavirus (COVID-19) and People with Diabetes. (American Association of Clinical Endocrinologists, 2020). https://www.aace.com/recent-news-and-updates/aace-position-statement-coronavirus-covid-19-and-people-diabetes-updated. Accessed 21 Apr 2020

181.

M. Nacoti, A. Ciocca, A. Giupponi et al. At the epicenter of the Covid-19 pandemic and humanitarian crises in Italy: changing perspectives on preparation and mitigation. NEJM Catalyst innovations in care delivery (2020). https://doi.org/10.1056/CAT.20.0080

182.

H.R. Murphy, Managing diabetes in pregnancy before, during, and after COVID-19. Diabetes Technol. Ther. 22(6), 454–461 (2020). https://doi.org/10.1089/dia.2020.0223CrossRefPubMed

183.

R.M. Anjana, R. Pradeepa, M. Deepa et al. Acceptability and utilization of newer technologies and effects on glycemic control in type 2 diabetes: lessons learnt from lockdown. Diabetes Technol Ther. (2020). https://doi.org/10.1089/dia.2020.0240

184.

H. McGloin, D. O’Connell, M. Glacken et al. Patient empowerment using electronic telemonitoring with telephone support in the transition to insulin therapy in adults with type 2 diabetes: observational, pre-post, mixed methods study. J. Med. Internet Res. 22(5), e16161 (2020). https://doi.org/10.2196/16161CrossRefPubMedPubMedCentral

Title: Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review
Authors: Giuseppe Lisco
Anna De Tullio
Vito Angelo Giagulli
Edoardo Guastamacchia
Giovanni De Pergola
Vincenzo Triggiani
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Obesity
Obesity
SARS-CoV-2
COVID-19
Diabetes
Type 2 Diabetes
Published in: Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02444-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

Insulin gene mutations and posttranslational and translocation defects: associations with diabetes

Etiology, baseline clinical profile and comorbidities of patients with Cushing’s syndrome at a single endocrinological center

Apparent Mineralocorticoid Excess: Research as an Art Form

Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients

The 2039 A/G FSH receptor gene polymorphism influences glucose metabolism in healthy men

Correction to: A mutation in NOTCH2 gene first associated with Hajdu–Cheney syndrome in a Greek family: diversity in phenotype and response to treatment

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage